California in October became the latest state to reject a controversial bill designed to stop automatic substitution of brand-name biologics for interchangeable biosimilars. The bill, backed by innovator biotechs such as Amgen and Genentech, pushes for biosimilars to be defined as interchangeable by the US Food and Drug Administration before pharmacists can substitute them as a default practice. The legislation has failed to pass in 11 states.
Rights and permissions
About this article
Cite this article
Biosimilars legislation state by state. Nat Biotechnol 31, 947 (2013). https://doi.org/10.1038/nbt1113-947
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1113-947
This article is cited by
-
What's fueling the biotech engine—2012 to 2013
Nature Biotechnology (2014)